歐洲藥品管理局發布人工智慧工作計畫,提出四大策略領域
2023 年 12 月 18 日,歐洲藥品管理局(European Medicines Agency, EMA)和成員國藥品管理局(Member State Heads of Medicines Agencies, HMA)發布了人工智慧工作計畫,其係規劃自 2023 年到 2028 年的策略,旨在最大化 AI 為利益相關者帶來的好處,同時管理風險。工作計畫中涵蓋四個重點工作領域,包括指南、政策和產品支援(Guidance, policy and product support);AI 工具和技術(AI tools and technology);合作和培訓(Collaboration and training);實驗(Experimentation)。
=====
2024年預計要達成的事情還不少,包括
Guidance, policy and product support 中有
• Q3 2024 –preparation for the AI Act
• Q4 2024 –phased implementation of an AI Observatory
Tools & technologies 以及 Collaboration and change management 中有
• Q1 2024 –initial knowledge mining tools to be rolled out for the Network
• Q2 2024 –phased roll-out and monitoring of LLMs and related chatbots as personal assistants
• Q3 2024 –completed survey of the network on capability to analyse data
• Q4 2024 –publication of the AI tools policy for the EMRN
Experimentation 中有
• Q1 2024 –first workplan experimentation cycle
• Q2 2024/2026 – technical deep dives
資料來源:Artificial intelligence workplan to guide use of AI in medicines regulation
留言